Prosecution Insights
Last updated: April 19, 2026
Application No. 18/651,043

CITRIC ACID AND LACTIC ACID DISINFECTING SOLUTION FOR SOFT POROUS SURFACES

Non-Final OA §103
Filed
Apr 30, 2024
Examiner
WEBB, WALTER E
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Clorox Company
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
3y 0m
To Grant
66%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allow Rate
454 granted / 977 resolved
-13.5% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
60 currently pending
Career history
1037
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
48.3%
+8.3% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
15.4%
-24.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 977 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. 1) Claim(s) 1-4, 6-8, 10-11 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cheung et al., (GB 2379223, pub. 2003). Cheung et al. teaches cleaning compositions comprising citric acid, wherein the composition “comprises either citric acid alone or citric acid in combination with an acid selected from the group consisting of . . . lactic acid . . .and mixtures thereof; 0.001-10% by weight of at least one anionic surfactant; 0.001-5% by weight of a thickener . . . ; 0-10% by weight of one or more optional constituents; and the balance to 100% by weight, water; wherein the aqueous hard surface cleaning composition exhibits a pH of 6.0 or less. Typically, citric acid is used in combination with lactic acid, glycolic acid or malic acid” (Abstract). The reference teaches a specific embodiment below: PNG media_image1.png 601 806 media_image1.png Greyscale (p. 10). Note: Example 740-146A combines 2.0% citric acid with 2.3% lactic acid and sodium lauryl sulfate (Stepanol WAC; anionic surfactant; sulfate (clm. 6)), as the non-ethoxylated surfactant. Although, the ratio of citric acid to lactic acid is 2/2.024, in this embodiment, falls outside of the clamed ratio of about 3:1 to about, the amount of citric acid in combination with lactic acid can be adjusted. The reference states, “The acid constituent is desirably present in the formulations such that with the presence of optional ingredients taken into account, the pH of the formulation is at a pH of less than 6 . . . The pH range represents an amount of acid from about 0.5 to about 10% by weight based on the total weight of the composition. Based on this, it is within the scope of the prior art to formulate a composition having a 3% citric acid and 1% lactic acid, this providing the claimed ratio of about 3:1. The acids are also taught to be result effective variables insofar as they “are selected to feature disinfecting properties, they concomitantly provide anti-microbial activity necessary to disinfect the cleaned surface” (p. 2, lines 7-13). Accordingly, "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation" (see MPEP 2144.05 IIA quoting In re Aller, 220 F.2d 454, 456 (105 USPQ 233)). Preservatives may also be added in minor amounts in the formulations, i.e., “amounts of about 0.5% by weight of the total composition, more generally an amount of about 0.1% by weight and less, and preferably is present in amounts of about 0.05% by weight and less” (p. 6, lines 2-10). In regard to claim 3-4, 7, 12, “nonionic surfactants” (p. 4, line 4) and surfactants with “sulfate” (see Table 1 above), surfactants with “amine oxides” (p. 4, lines 11-13) may also be included. The prior art is not anticipatory insofar as it does not provide the claimed ratio of citric acid to lactic acid nor require a preservative. However, it would have been obvious to add the preservative based on its plan enumeration in the prior art. It would have also been obvious to a person having ordinary skill in the art at the time of applicant’s filing to modify the ratio of citric acid to lactic acid for the purpose of disinfecting a surface. The adjustment of particular conventional working conditions of citric acid and lactic acid (e.g., determining result effective amounts of the ingredients beneficially taught by the cited references), is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. Accordingly, this type of modification would have been well within the purview of the skilled artisan and no more than an effort to optimize results. Since the prior art anticipates the combination of citric acid and lactic acid the prior art would have been capable of exhibiting at least a 3-log or 5-log reduction in Staphylococcus aureus population within 10 minutes. 2) Claim(s) 5, 9, 12-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cheung et al., (GB 2379223, pub. 2003) as applied to claims 1-4, 6-8, 10-11 above, and further in view of O’Connell et al., (US 2010/0330013). Cheung et al., which is taught above, differs from claims 5, 9, 12-20 insofar as it does not teach where the surfactant is amphoteric or alkyl polyglucoside, sodium benzoate, benzoic acid, or where the solvent is an alcohol or diol. O’Connell et al. teaches cleaning products “disinfectants” for “disinfection and treatment of filter media, textiles, furs, paper, skins or leather, and other products containing amadoriases” (Abstract). Suitable ingredients for use in disinfectant compositions, taught therein, include “amphoteric surfactants” (p. 18, para. [0200]); “benzoic acid” and “benzoates” (p. 14, para. [0163]); “alkyl polyglucosides” as non-ionic surfactant (p. 6, para. [0090]) and “Solvents” such as “polyhydric alcohols” (p. 12, para. [0144]), which may be present “in amounts between 0.1 and 20 wt.%” (Id. para. [0145]). “The selection of a known material based on its suitability for its intended use supported a prima facie obviousness determination in Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945)” (see MPEP 2144.07). It would have been obvious to a person having ordinary skill in the art to add an amphoteric surfactant, sodium benzoate, benzoic acid, alkyl polyglucoside, and alcohol solvent to the disinfectant of Cheung et al. based on their art recognized suitability for their intended used in disinfectant formulations, as taught by O’Connell et al. Conclusion Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WALTER E WEBB whose telephone number is (571)270-3287 and fax number is (571) 270-4287. The examiner can normally be reached from Mon-Fri 7-3:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Walter E. Webb /WALTER E WEBB/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Apr 30, 2024
Application Filed
Feb 18, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582600
STABLE GEL COMPOSITION HAVING HIGH OIL CONTENT, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570932
REMOVAL AND PREVENTION OF BIOFILM BY NANOPARTICLE CHEMISTRIES
2y 5m to grant Granted Mar 10, 2026
Patent 12564657
MOULDABLE ARTIFICIAL BONE COMPOSITE MATERIAL AND PREPARATION METHOD THEREOF
2y 5m to grant Granted Mar 03, 2026
Patent 12564544
THICKENED ALKALYZATION COMPONENT FOR OXIDATIVE HAIR LIGHTENING PRODUCT
2y 5m to grant Granted Mar 03, 2026
Patent 12551425
AQUEOUS ZINC ORAL CARE COMPOSITIONS WITH FLUORIDE
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
66%
With Interview (+19.0%)
3y 0m
Median Time to Grant
Low
PTA Risk
Based on 977 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month